O3.2 - Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A
| Autor: | Seymour, L., Tinker, A., Hirte, H., Wagtmann, N., Dodion, P. |
|---|---|
| Zdroj: | In Annals of Oncology March 2015 26 Supplement 2:ii3-ii3 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|